Skip to content
Biotechnology, Business Company News

Optiscan Imaging (ASX:OIL) December 2024 Quarterly Report and Appendix 4C

Optiscan Imaging Limited (ASX:OIL) 3 mins read

Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or the ‘Company’), a leader in medical imaging using confocal laser endomicroscopy, is pleased to announce its Appendix 4C Quarterly Cashflow report and business update for the quarter ended 31 December 2024 (the ‘Quarter’). All financial results are in Australian dollars and are unaudited.

Highlights for the Quarter

• Product development and clinical pipeline achievements over the Quarter included: 

➢ The signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine
➢ The development of a dedicated veterinary imaging product was commenced
➢ The signing of an agreement with Monash University to develop AI technology solutions for gastroenterology imaging
➢ The completion of key CRC-P grant milestones, securing additional $0.398m of funding.

• In a key equipment deliverable, Optiscan provided the first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz for evaluation.
• Substantial progress made on the InVue® product development, with delivery on track to support the clinical evidence generation programs at the Royal Melbourne Hospital and Mayo Clinic.
• Delivery of a ViewnVivo® system to China-based distribution partner following a sale to a large Chinese university; Increased Business Development activities resulted in two ViewnVivo® funding applications in China; Quotes for ViewnVivo® sale issued to two Tier 1 research universities in the US.
• Multiple brand awareness initiatives also occurred over the Quarter including attendance at American College of Veterinary Pathologists and American College of Veterinary Surgeons meetings.

Optiscan’s Chief Executive Officer and Managing Director, Dr. Camile Farah, commented:

“Optiscan enjoyed a highly successful December 2024 quarter, as it continued to advance its core priorities that cut across R&D, commercialization, and market expansion, headlined by the achievement of multiple milestones that position the Company for sustained growth. Key highlights over the Quarter were delivery of our first flexible GI scope prototype to University Medical Centre of the Johannes Gutenberg University Mainz for evaluation and the signing of a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine for veterinary imaging applications. At the same time, our team substantially progressed the Company’s InVue® product development program, delivered a ViewnVivo® system to Chinabased distribution partner, and pulled out all stops to bolster market awareness of Optiscan’s expanding MedTech offering.

These accomplishments reflect our commitment to innovation, not only in addressing immediate market needs but also in laying the foundation for long-term leadership in precision imaging. By focusing on strategic partnerships and transformative technologies, we are building a future where Optiscan’s solutions redefine standards in healthcare and research, delivering lasting value for the medical community, patients, and our shareholders.” 


About us:

About Optiscan Imaging

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan’s patented technology produces super high-resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan’s medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients. 

To learn more about Optiscan, visit www.optiscan.com 


Contact details:

Shareholder & General Enquiries
Optiscan Imaging Ltd
Dr Camile Farah
+61 3 9538 3333
[email protected]

Media & Investor Enquiries
The Capital Network
Julia Maguire
+61 2 7257 7338
[email protected]

More from this category

  • Business Company News
  • 17/06/2025
  • 13:25
Staffbase

Bestselling author Malcolm Gladwell and Thrive Global founder Arianna Huffington spearheaded Staffbase’s VOICES 2025 for Internal Communicators

Key takeaways from the largest virtual employee communications event, uniting 3,000+ comms and human resources professionalsSYDNEY, June 17, 2025 (GLOBE NEWSWIRE) -- Staffbase, the leading employee communications cloud provider, hosted VOICES 2025, the world’s largest virtual event for internal communicators and HR professionals, in APAC timezone on June 11, 2025. The event featured top industry voices addressing today’s most critical challenges in employee communications and people strategy.As economic uncertainty, policy shifts, and internal transformations persist, it's more critical than ever for employee communicators to have a voice at the executive table. Burnout is on the rise and disengagement is costing…

  • Agriculture Farming Rural, Business Company News
  • 17/06/2025
  • 11:42
Avocados Australia

Australian avocado experts coming to Stuarts Point!

Avocados are packed full of nutrition and offer many health benefits.* In 2023/24 Australian avocado growers produced 150,913 tonnes of avocados supplying all year…

  • Contains:
  • Business Company News, Information Technology
  • 17/06/2025
  • 10:38
ASUS Australia

ASUS Republic of Gamers Announces ROG Strix GS-BE18000 WiFi 7 Gaming Router

Featuring wired capacity of 20G via eight ports, two dedicated gaming ports, up to three SSIDs for gaming, IoT device support, VPN support &…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.